These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 30617131

  • 1. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
    Boeri M, Milione M, Proto C, Signorelli D, Lo Russo G, Galeone C, Verri C, Mensah M, Centonze G, Martinetti A, Sottotetti E, Pastorino U, Garassino MC, Sozzi G.
    Clin Cancer Res; 2019 Apr 01; 25(7):2166-2173. PubMed ID: 30617131
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K, Miura S, Sakaguchi T, Murotani K, Horita N, Akamatsu H, Uemura K, Morita S, Yamamoto N.
    Lung Cancer; 2019 Feb 01; 128():113-119. PubMed ID: 30642442
    [Abstract] [Full Text] [Related]

  • 4. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
    Lang D, Horner A, Brehm E, Akbari K, Hergan B, Langer K, Asel C, Scala M, Kaiser B, Lamprecht B.
    Lung Cancer; 2019 Aug 01; 134():59-65. PubMed ID: 31319996
    [Abstract] [Full Text] [Related]

  • 5. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H, Qin N, Yu M, Ma L, Wu Y, Zhang H, Zhang X, Li X, Wang J.
    Zhongguo Fei Ai Za Zhi; 2021 Mar 20; 24(3):161-166. PubMed ID: 33819965
    [Abstract] [Full Text] [Related]

  • 6. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
    Chen Y, Liu Q, Chen Z, Wang Y, Yang W, Hu Y, Han W, Zeng H, Ma H, Dai J, Zhang H.
    J Exp Clin Cancer Res; 2019 May 14; 38(1):193. PubMed ID: 31088500
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
    Tarhoni I, Wakefield CJ, Kollipara R, Fidler MJ, Batus M, Bonomi P, Borgia JA.
    J Immunol Methods; 2021 Mar 14; 490():112956. PubMed ID: 33434603
    [Abstract] [Full Text] [Related]

  • 9. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y, Lei Y, Liu L, Zhang S, Wang W, Zhao J, Zhao S, Dong X, Yao M, Wang K, Zhou Q.
    Cancer Med; 2021 Apr 14; 10(7):2216-2231. PubMed ID: 33655698
    [Abstract] [Full Text] [Related]

  • 10. PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.
    Li J, Gu J.
    Future Oncol; 2019 May 14; 15(14):1667-1678. PubMed ID: 31041879
    [Abstract] [Full Text] [Related]

  • 11. Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
    Kim H, Lim DH, Kwon YS, Kim MA, Park KU.
    Anticancer Res; 2023 May 14; 43(5):2343-2349. PubMed ID: 37097676
    [Abstract] [Full Text] [Related]

  • 12. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
    Zhang B, Liu Y, Zhou S, Jiang H, Zhu K, Wang R.
    Int Immunopharmacol; 2020 Mar 14; 80():106214. PubMed ID: 31982822
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of programmed cell death ligand 1 blood markers in non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Zhang N, Chang J, Liu P, Tian X, Yu J.
    Front Immunol; 2024 Mar 14; 15():1400262. PubMed ID: 38915398
    [Abstract] [Full Text] [Related]

  • 14. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H, Liu L, Peng Q, Chen J, Zhu YD.
    BMC Cancer; 2021 Nov 13; 21(1):1220. PubMed ID: 34774004
    [Abstract] [Full Text] [Related]

  • 15. Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.
    Yang Q, Chen M, Gu J, Niu K, Zhao X, Zheng L, Xu Z, Yu Y, Li F, Meng L, Chen Z, Zhuo W, Zhang L, Sun J.
    Front Immunol; 2021 Nov 13; 12():665133. PubMed ID: 33936103
    [Abstract] [Full Text] [Related]

  • 16. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S, Theou-Anton N, Nguenang M, Cazes A, Danel C, Abbar B, Pluvy J, Gounant V, Khalil A, Namour C, Brosseau S, Zalcman G.
    Lung Cancer; 2019 Jun 13; 132():65-71. PubMed ID: 31097096
    [Abstract] [Full Text] [Related]

  • 17. PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.
    Yoshida H, Nomizo T, Ozasa H, Tsuji T, Funazo T, Yasuda Y, Ajimizu H, Yamazoe M, Kuninaga K, Ogimoto T, Hosoya K, Itotani R, Sakamori Y, Kim YH, Hirai T.
    Eur J Cancer; 2021 Feb 13; 144():317-325. PubMed ID: 33385948
    [Abstract] [Full Text] [Related]

  • 18. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ, Zhu HH, Liu YT, Lin L, Xing PY, Hao XZ, Cong MH, Wang HY, Wang Y, Li JL, Feng Y, Hu XS.
    Zhonghua Zhong Liu Za Zhi; 2022 May 23; 44(5):416-424. PubMed ID: 35615798
    [Abstract] [Full Text] [Related]

  • 19. Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients.
    Hurkmans DP, Kuipers ME, Smit J, van Marion R, Mathijssen RHJ, Postmus PE, Hiemstra PS, Aerts JGJV, von der Thüsen JH, van der Burg SH.
    Cancer Immunol Immunother; 2020 May 23; 69(5):771-777. PubMed ID: 32047958
    [Abstract] [Full Text] [Related]

  • 20. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N, Ichihara E, Takigawa N, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Oda N, Hara N, Hotta K, Maeda Y, Kiura K.
    Eur J Cancer; 2021 May 23; 149():73-81. PubMed ID: 33838391
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.